Peripheral Blood Inflammatory Biomarkers Dynamics Reflect Treatment Response and Predict Prognosis in Non-small Cell Lung Cancer Patients with Neoadjuvant Immunotherapy

Overview

Journal Cancer Sci

Specialty Oncology

Date 2023 Sep 21

PMID 37731264

Authors

Qilin Huai

Chenyu Luo

Peng Song

Fenglong Bie

Guangyu Bai

Yuan Li

Yang Liu

Xiaowei Chen

Bolun Zhou

Xujie Sun

Wei Guo

Shugeng Gao

Affiliations

Soon will be listed here.

Abstract

Neoadjuvant immunotherapy has significantly changed the therapeutic approach for treating patients with surgically resectable non-small cell lung cancer (NSCLC). Here, peripheral blood inflammation-based biomarkers as well as previously less focused eosinophil fraction, modified Glasgow prognostic score (mGPS), and prognostic nutritional index (PNI) were systematically included to comprehensively analyze their potential in predicting neoadjuvant immunotherapy efficacy and prognosis. We enrolled 189 patients (94 in training and 95 in validation cohorts) with stage I-III B surgically resectable NSCLC treated with neoadjuvant immunotherapy from the National Cancer Center of China. Baseline and post-treatment eosinophils fraction, neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), systemic immune-inflammation index (SII), monocyte-to-lymphocyte ratio (MLR), PNI, mGPS, and their changes were calculated and analyzed for correlation with neoadjuvant immunotherapy efficacy and prognosis. In patients in the major pathological response (MPR) group, the post-treatment eosinophil fraction was significantly high, and NLR, PLR, SII, and MLR were significantly lower compared to the non-MPR group in both the training and validation cohorts. The receiver operating characteristic curve showed that post-treatment, eosinophil fraction and SII and their changing were two of the most important factors. Univariate and multivariate logistic regression analyses showed that post-treatment eosinophil fraction, SII, mGPS, and ΔSII could independently predict MPR in patients treated with neoadjuvant immunotherapy. Survival analysis showed a significant correlation between high post-treatment NLR, PLR, SII, mGPS, and their changes in ΔNLR and ΔSII elevation with poor overall survival and event-free survival of patients. Our results suggest that inflammatory biomarkers could predict the patient's response to neoadjuvant immunotherapy and prognosis.

Citing Articles

Predictive value of preoperative systemic immune-inflammation index and prognostic nutrition index in patients with epithelial ovarian cancer.

Chen J, Jin L, Luo R, Zhang X, Chen Y, Han Z J Ovarian Res. 2025; 18(1):45.

PMID: 40055764 PMC: 11887369. DOI: 10.1186/s13048-025-01631-4.

Prognostic value of the lactate dehydrogenase to albumin ratio in advanced non-small cell lung cancer patients treated with the first-line PD-1 checkpoint inhibitors combined with chemotherapy.

Luo M, Wei H, Qiu M, Su C, Ning R, Zhou S Front Immunol. 2025; 16:1473962.

PMID: 40013138 PMC: 11861202. DOI: 10.3389/fimmu.2025.1473962.

Inverted U-shaped association between the systemic immune-inflammation index and colorectal polyps in Chinese patients: a cross-sectional study.

Bao J, Teng Y, Yang Y, Wang Q Front Med (Lausanne). 2025; 11:1515230.

PMID: 39931434 PMC: 11808360. DOI: 10.3389/fmed.2024.1515230.

Construction and evaluation of a prognostic model for cervical cancer based on dynamic hematological and clinical features.

Ma H, Ma L, Yang L, Cai M, Wang Y, Li Y BMC Cancer. 2025; 25(1):207.

PMID: 39910481 PMC: 11800499. DOI: 10.1186/s12885-025-13595-1.

Nomogram for prognosis prediction in metastatic pancreatic cancer patients undergoing intra-arterial infusion chemotherapy: incorporating immune-inflammation scores and coagulation indicators.

Yang Y, Zong S, Hua Y BMC Cancer. 2025; 25(1):107.

PMID: 39833690 PMC: 11749238. DOI: 10.1186/s12885-025-13523-3.

References

Reichman H, Itan M, Rozenberg P, Yarmolovski T, Brazowski E, Varol C . Activated Eosinophils Exert Antitumorigenic Activities in Colorectal Cancer. Cancer Immunol Res. 2019; 7(3):388-400. DOI: 10.1158/2326-6066.CIR-18-0494. View

Hanahan D, Weinberg R . Hallmarks of cancer: the next generation. Cell. 2011; 144(5):646-74. DOI: 10.1016/j.cell.2011.02.013. View

Carretero R, Sektioglu I, Garbi N, Salgado O, Beckhove P, Hammerling G . Eosinophils orchestrate cancer rejection by normalizing tumor vessels and enhancing infiltration of CD8(+) T cells. Nat Immunol. 2015; 16(6):609-17. DOI: 10.1038/ni.3159. View

Tong Y, Tan J, Zhou X, Song Y, Song Y . Systemic immune-inflammation index predicting chemoradiation resistance and poor outcome in patients with stage III non-small cell lung cancer. J Transl Med. 2017; 15(1):221. PMC: 5664920. DOI: 10.1186/s12967-017-1326-1. View

Inoue H, Shiozaki A, Fujiwara H, Konishi H, Kiuchi J, Ohashi T . Absolute lymphocyte count and C-reactive protein-albumin ratio can predict prognosis and adverse events in patients with recurrent esophageal cancer treated with nivolumab therapy. Oncol Lett. 2022; 24(2):257. PMC: 9219019. DOI: 10.3892/ol.2022.13377. View

Proctor M, Horgan P, Talwar D, Fletcher C, Morrison D, McMillan D . Optimization of the systemic inflammation-based Glasgow prognostic score: a Glasgow Inflammation Outcome Study. Cancer. 2013; 119(12):2325-32. DOI: 10.1002/cncr.28018. View

Li C, Wu J, Jiang L, Zhang L, Huang J, Tian Y . The predictive value of inflammatory biomarkers for major pathological response in non-small cell lung cancer patients receiving neoadjuvant chemoimmunotherapy and its association with the immune-related tumor microenvironment: a multi-center study. Cancer Immunol Immunother. 2022; 72(3):783-794. PMC: 10991885. DOI: 10.1007/s00262-022-03262-w. View

Forde P, Spicer J, Lu S, Provencio M, Mitsudomi T, Awad M . Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer. N Engl J Med. 2022; 386(21):1973-1985. PMC: 9844511. DOI: 10.1056/NEJMoa2202170. View

Ameratunga M, Chenard-Poirier M, Candilejo I, Pedregal M, Lui A, Dolling D . Neutrophil-lymphocyte ratio kinetics in patients with advanced solid tumours on phase I trials of PD-1/PD-L1 inhibitors. Eur J Cancer. 2017; 89:56-63. DOI: 10.1016/j.ejca.2017.11.012. View

10.

Houston K, Henley S, Li J, White M, Richards T . Patterns in lung cancer incidence rates and trends by histologic type in the United States, 2004-2009. Lung Cancer. 2014; 86(1):22-8. PMC: 5823254. DOI: 10.1016/j.lungcan.2014.08.001. View

11.

Nenclares P, Gunn L, Soliman H, Bover M, Trinh A, Leslie I . On-treatment immune prognostic score for patients with relapsed and/or metastatic head and neck squamous cell carcinoma treated with immunotherapy. J Immunother Cancer. 2021; 9(6). PMC: 8190047. DOI: 10.1136/jitc-2021-002718. View

12.

Eisenhauer E, Therasse P, Bogaerts J, Schwartz L, Sargent D, Ford R . New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2008; 45(2):228-47. DOI: 10.1016/j.ejca.2008.10.026. View

13.

Huai Q, Luo C, Song P, Bie F, Bai G, Li Y . Peripheral blood inflammatory biomarkers dynamics reflect treatment response and predict prognosis in non-small cell lung cancer patients with neoadjuvant immunotherapy. Cancer Sci. 2023; 114(12):4484-4498. PMC: 10728017. DOI: 10.1111/cas.15964. View

14.

Simon S, Hu X, Panten J, Grees M, Renders S, Thomas D . Eosinophil accumulation predicts response to melanoma treatment with immune checkpoint inhibitors. Oncoimmunology. 2020; 9(1):1727116. PMC: 7028332. DOI: 10.1080/2162402X.2020.1727116. View

15.

Fornarini G, Rebuzzi S, Banna G, Calabro F, Scandurra G, De Giorgi U . Immune-inflammatory biomarkers as prognostic factors for immunotherapy in pretreated advanced urinary tract cancer patients: an analysis of the Italian SAUL cohort. ESMO Open. 2021; 6(3):100118. PMC: 8134706. DOI: 10.1016/j.esmoop.2021.100118. View

16.

Noh G, Han J, Cho M, Hur H, Min B, Lee K . Impact of the prognostic nutritional index on the recovery and long-term oncologic outcome of patients with colorectal cancer. J Cancer Res Clin Oncol. 2017; 143(7):1235-1242. DOI: 10.1007/s00432-017-2366-x. View

17.

Rothschild S, Zippelius A, Eboulet E, Savic Prince S, Betticher D, Bettini A . SAKK 16/14: Durvalumab in Addition to Neoadjuvant Chemotherapy in Patients With Stage IIIA(N2) Non-Small-Cell Lung Cancer-A Multicenter Single-Arm Phase II Trial. J Clin Oncol. 2021; 39(26):2872-2880. DOI: 10.1200/JCO.21.00276. View

18.

Ferro M, Tataru O, Musi G, Lucarelli G, Abu Farhan A, Cantiello F . Modified Glasgow Prognostic Score as a Predictor of Recurrence in Patients with High Grade Non-Muscle Invasive Bladder Cancer Undergoing Intravesical Bacillus Calmette-Guerin Immunotherapy. Diagnostics (Basel). 2022; 12(3). PMC: 8947693. DOI: 10.3390/diagnostics12030586. View

19.

Kim Y . Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. N Engl J Med. 2019; 380(10):989-990. DOI: 10.1056/NEJMc1900407. View

20.

Pless M, Stupp R, Ris H, Stahel R, Weder W, Thierstein S . Induction chemoradiation in stage IIIA/N2 non-small-cell lung cancer: a phase 3 randomised trial. Lancet. 2015; 386(9998):1049-56. DOI: 10.1016/S0140-6736(15)60294-X. View